Advaxis Inc. buy tamam
Zusammenfassung
Diese Einschätzung wurde am 01.02.19 mit einem Endkurs von 5,13 € beendet. Stark abwärts ging es für die BUY Einschätzung von tamam zu Advaxis Inc. mit einer Rendite von -91,14 %. tamam hat 50% Zuversicht bei dieser EinschätzungRendite ohne Dividenden (%)
Name | 1W | 1M | 1J | 3J |
---|---|---|---|---|
Advaxis Inc. | - | - | - | - |
iShares Core DAX® | -1,11 % | 3,43 % | 25,97 % | 25,04 % |
iShares Nasdaq 100 | 1,82 % | 6,91 % | 30,39 % | 48,14 % |
iShares Nikkei 225® | 2,11 % | 5,50 % | 23,40 % | 11,98 % |
iShares S&P 500 | 2,04 % | 5,33 % | 30,88 % | 46,98 % |
Kommentare von tamam zu dieser Einschätzung
In der Diskussion Advaxis Inc. diskutieren
ADXS has very interesting make-or-break potential, caveat emptor!
One can be tentatively optimistic in the ability of ADXS to move the needle in its late-stage clinical programs. Cervical cancer remains a substantial unmet need, and the company is moving aggressively toward filing for approval in Europe. One highly encouraging sign, in my mind, is the tacit endorsement from 3 out of the 5 big immune checkpoint developers. BMY, MRK, and AZN are all collaborating with ADXS in some way. By no means is ADXS the only partner for the immune checkpoints, but this is a positive sign for me.
Cantor Fitzgerald reiterates buy rating with target of $19.00.
https://www.advaxis.com/wp-content/uploads/2017/06/A-recombinant-HER2-Neu.pdf